HR Execs on the Move

Center for Breakthrough Medicines

www.breakthroughmedicines.com

 
The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Joseph Lingle
Chief People Officer Profile
Marla Dissin
Director of Human Resources Profile
Holly Foster
Chief People Officer Profile

Similar Companies

Aids Vaccine Advocacy Coalition

Aids Vaccine Advocacy Coalition is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

biozeen

biozeen is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

GentiBio

GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.

CytomX

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.